ArticlePLoS neglected tropical diseases2013
Temephos resistance in Aedes aegypti in Colombia compromises dengue vector control.
Article in PLoS neglected tropical diseases, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Is Dengue Vector Control Deficient in Effectiveness or Evidence?: Systematic Review and Meta-analysis.PLoS neglected tropical diseases · 2016Pooled it
- Using a digital health tool to strengthen community engagement in arboviral disease prevention: an implementation study in Colombia.BMC public health · 2026Trial
- The influence of gender and temephos exposure on community participation in dengue prevention: a compartmental mathematical model.BMC infectious diseases · 2024Trial
- Beyond efficacy in water containers: Temephos and household entomological indices in six studies between 2005 and 2013 in Managua, Nicaragua.BMC public health · 2017Trial
- Coverage and beliefs about temephos application for control of dengue vectors and impact of a community-based prevention intervention: secondary analysis from the Camino Verde trial in Mexico.BMC public health · 2017Trial
- Green Chemistry Oriented Pluronic F127/Carbopol Nanogel Platform (NGLp) EncapsulatingACS omega · 2026Article
- Thermoresponsive Nanogel IncorporatingACS omega · 2026Article
- The contribution of transposable element insertions to genetic diversity inbioRxiv : the preprint server for biology · 2025Article
- Susceptibility ofInsects · 2025Article
- Characterization of the transcriptional cellular response in midgut tissue of temephos-resistant Aedes aegypti larvae.Parasites & vectors · 2025Article
- Omics Approaches in Understanding Insecticide Resistance in Mosquito Vectors.International journal of molecular sciences · 2025Review
- Diversity of Gut Bacteria of Field-CollectedInsects · 2025Article
- Susceptibility to organophosphate insecticides in Aedes aegypti (Diptera: Culicidae) from northern Colombia and associated resistance mechanisms.Parasites & vectors · 2025Article
- In vitro evaluation of the pathogenicity of fungi isolated from the Urabá region (Antioquia, Colombia) against Aedes aegypti larvaeBiomedica : revista del Instituto Nacional de Salud · 2024Article
- Widespread Resistance to Temephos inInsects · 2024Article
- Evaluation of susceptibility to organophosphates in populations of Aedes aegypti in La Guajira, ColombiaBiomedica : revista del Instituto Nacional de Salud · 2023Article
- Spent Coffee Grounds and Novaluron Are Toxic toInsects · 2023Article
- Worldwide Status of Insecticide Resistance ofJournal of arthropod-borne diseases · 2023Review
- The use of drones for mosquito surveillance and control.Parasites & vectors · 2022Review
- Expansive and Diverse Phenotypic Landscape of Field Aedes aegypti (Diptera: Culicidae) Larvae with Differential Susceptibility to Temephos: Beyond Metabolic Detoxification.Journal of medical entomology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundControl and prevention of dengue relies heavily on the application of insecticides to control dengue vector mosquitoes. In Colombia, application of the larvicide temephos to the aquatic breeding sites of Aedes aegypti is a key part of the dengue control strategy. Resistance to temephos was recently detected in the dengue-endemic city of Cucuta, leading to questions about its efficacy as a control tool. Here, we characterize the underlying mechanisms and estimate the operational impact of this resistance. METHODOLOGY/PRINCIPAL
findingsLarval bioassays of Ae. aegypti larvae from Cucuta determined the temephos LC50 to be 0.066 ppm (95% CI 0.06-0.074), approximately 15× higher than the value obtained from a susceptible laboratory colony. The efficacy of the field dose of temephos at killing this resistant Cucuta population was greatly reduced, with mortality rates <80% two weeks after application and <50% after 4 weeks. Neither biochemical assays nor partial sequencing of the ace-1 gene implicated target site resistance as the primary resistance mechanism. Synergism assays and microarray analysis suggested that metabolic mechanisms were most likely responsible for the temephos resistance. Interestingly, although the greatest synergism was observed with the carboxylesterase inhibitor, DEF, the primary candidate genes from the microarray analysis, and confirmed by quantitative PCR, were cytochrome P450 oxidases, notably CYP6N12, CYP6F3 and CYP6M11. CONCLUSIONS/SIGNIFICANCE: In Colombia, resistance to temephos in Ae. aegypti compromises the duration of its effect as a vector control tool. Several candidate genes potentially responsible for metabolic resistance to temephos were identified. Given the limited number of insecticides that are approved for vector control, future chemical-based control strategies should take into account the mechanisms underlying the resistance to discern which insecticides would likely lead to the greatest control efficacy while minimizing further selection of resistant phenotypes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.